Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL4059260 | 1.00 | ALOX15 (0.45) | ALOX15BLMPMP22KMT2AGRM8 | |
| Arginine SCHEMBL6517506 | 0.96 | ALOX15 (0.49) | ALOX15BLMPMP22KMT2ABHMT | |
| Arginine SCHEMBL18660568 | 0.96 | ALOX15 (0.49) | ALOX15BLMPMP22KMT2ABHMT | |
| Arginine SCHEMBL4052601 | 0.96 | ALOX15 (0.49) | ALOX15BLMPMP22KMT2ABHMT | |
| Arginine SCHEMBL20138208 | 0.96 | ALOX15 (0.41) | ALOX15BLMPMP22KMT2AGRM8 | |
| Acetylglutamic Acid SCHEMBL365384 | 0.91 | FNTA (0.42) | ALOX15BLMPMP22KMT2AFNTA | |
| Aceglumate SCHEMBL28443403 | 0.91 | FNTA (0.42) | ALOX15BLMPMP22KMT2AFNTA | |
| Aceglumate SCHEMBL21055962 | 0.91 | FNTA (0.42) | ALOX15BLMPMP22KMT2AFNTA | |
| Aceglumate SCHEMBL28885877 | 0.91 | FNTA (0.42) | ALOX15BLMPMP22KMT2AFNTA | |
| Arginine SCHEMBL1766048 | 0.90 | OTC (0.46) | KMT2ABHMTFNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035443-B1 | STABILIZED VITAMIN C DERIVATIVES HAVING A PEPTIDE MOLECULE, PREPARATION METHOD THEREOF, AND COMPOSITION CONTAINING THE SAME | PEPTRON CO LTD (KR) | 2017-03-29 | — | — | EP | claimed |
| US-8829044-B2 | Stabilized vitamin C derivatives having a peptide molecule, preparation method thereof, and composition containing the same | Peotron Co. Ltd. (KR) | 2014-09-09 | — | — | US | claimed |
| US-20100331260-A1 | Stabilized bitamin c derivatives having a peptide molecule, preparation method thereof, and composition containing the same | Peptron Co.Ltd. (KR) | 2010-12-30 | — | — | US | claimed |
| EP-2035443-A1 | STABILIZED VITAMIN C DERIVATIVES HAVING A PEPTIDE MOLECULE, PREPARATION METHOD THEREOF, AND COMPOSITION CONTAINING THE SAME | Peptron Co., Ltd. (KR) | 2009-03-18 | — | — | EP | claimed |
| WO-2007148847-A1 | STABILIZED VITAMIN C DERIVATIVES HAVING A PEPTIDE MOLECULE, PREPARATION METHOD THEREOF, AND COMPOSITION CONTAINING THE SAME | PEPTRON CO., LTD. (KR) | 2007-12-27 | — | — | WO | claimed |
| EP-3271012-A1 | METHODS OF PROVIDING SKIN CARE USING PHOTOTHERAPY | Inderm (FR) | 2018-01-24 | — | — | EP | disclosed |
| EP-2035443-B1 | STABILIZED VITAMIN C DERIVATIVES HAVING A PEPTIDE MOLECULE, PREPARATION METHOD THEREOF, AND COMPOSITION CONTAINING THE SAME | PEPTRON CO LTD (KR) | 2017-03-29 | — | — | EP | disclosed |
| WO-2016146778-A1 | METHODS OF PROVIDING SKIN CARE USING PHOTOTHERAPY | INDERM (FR) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016040931-A1 | ANTI-AGING SKIN CARE COMPOSITIONS AND REGIMENS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
| US-8829044-B2 | Stabilized vitamin C derivatives having a peptide molecule, preparation method thereof, and composition containing the same | Peotron Co. Ltd. (KR) | 2014-09-09 | — | — | US | disclosed |
| US-20120065131-A1 | COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF AN OLIGOPEPTIDE | REVANCE THERAPEUTICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8022179-B2 | Compositions and methods for topical application and transdermal delivery of an oligopeptide | REVANCE THERAPEUTICS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2018148-A2 | METHOD OF ENHANCING PENETRATION OF WATER-SOLUBLE ACTIVES | The Procter and Gamble Company (US) | 2009-01-28 | — | — | EP | disclosed |
| WO-2009004516-A1 | PERSONAL CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008112964-A1 | PERSONAL CARE KIT HAVING SKIN CARE COMPOSITIONS WITH A READILY PERCEPTIBLE DIFFERENCE | THE PROCTER & GAMBLE COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007148847-A1 | STABILIZED VITAMIN C DERIVATIVES HAVING A PEPTIDE MOLECULE, PREPARATION METHOD THEREOF, AND COMPOSITION CONTAINING THE SAME | PEPTRON CO., LTD. (KR) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007133768-A2 | METHOD OF ENHANCING PENETRATION OF WATER-SOLUBLE ACTIVES | THE PROCTER & GAMBLE COMPANY (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1856139-A2 | COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF AN OLIGOPEPTIDE | Revance Therapeutics, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070037252-A1 | Compositions and methods for topical application and transdermal delivery of an oligopeptide | REVANCE THERAPEUTICS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2006094193-A2 | COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF AN OLIGOPEPTIDE | REVANCE THERAPEUTICS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331260-A1 | Stabilized bitamin c derivatives having a peptide molecule, preparation method thereof, and composition containing the same | PROC, CTRC, TTPA | ALOX15 3624/4885BLM 2505/4885PMP22 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.